Protagonist Therapeutics, INC (PTGX) SEC Filings — 2025

Filings

• Protagonist Swings to Loss on Plummeting Collaboration Revenue — 10-Q · Nov 6, 2025
• Protagonist Therapeutics Files 8-K on Financials — 8-K · Aug 6, 2025
• Protagonist's Q2 Loss Widens to $35.2M Amid Rusfertide Development — 10-Q · Aug 6, 2025
• Protagonist Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Jun 26, 2025
• Protagonist Therapeutics Files 8-K on Financials — 8-K · May 6, 2025
• Protagonist Therapeutics Files Q1 2025 10-Q — 10-Q · May 6, 2025
• Protagonist Therapeutics Files 2025 Proxy Statement — DEF 14A · Apr 29, 2025
• Protagonist Therapeutics Files 8-K — 8-K · Mar 20, 2025
• Protagonist Therapeutics Files 8-K/A Amendment — 8-K/A · Mar 11, 2025
• Protagonist Therapeutics Files 8-K — 8-K · Mar 10, 2025
• Protagonist Therapeutics Files 8-K — 8-K · Mar 3, 2025
• Protagonist Therapeutics Files 8-K on Financials — 8-K · Feb 21, 2025
• Protagonist Therapeutics Files 2024 10-K — 10-K · Feb 21, 2025
• Protagonist Therapeutics Announces Executive and Director Compensation Changes — 8-K · Jan 6, 2025